Program Faculty

​ ​Lauren H. MacyLauren H. Macy, an Improvement Advisor IHI, serves on IHI's Improvement Science and Methods Portfolio and teaches in IHI programs across a variety of settings and topic areas. Ms. Macy first started practicing improvement science with IHI in Ghana as part of the Project Fives Alive! initiative, a seven-year project funded by the Bill and Melinda Gates Foundation with the goal to reduce mortality in children in Ghana under age five using quality improvement methods. After seeing the impact of improvement science in strengthening a health system and helping the daily lives of mothers and children, she grew inspired to teach and coach others to improve. Ms. Macy serves as Director and faculty for IHI's Improvement Coach Professional Development Program and leads the curriculum development and teaching for IHI's internal staff improvement capability efforts. She also serves as Improvement Advisor on IHI's internal equity improvement team.​​​​​​

​ ​Kendra NjokuKendra Njoku, MBBS, MScPH, FISQua, is a medical doctor and public health professional with over 15 years of wide and varied experience in global health both at the local and international frontiers. She has driven innovations resulting in health system strengthening, supporting multiple governments, organizations, and health facilities. Her expertise and experience spread across quality management, patient safety, digital health solutions, data management, capacity building, self-care management and disease management. Dr. Njoku serves as Faculty/Improvement Advisor at IHI. In this role, she supports several countries and organizations across the Africa and Middle East/Asia regions in using quality improvement methodologies to achieve the SDG3 goals. Through her support and capacity building, the impact of large-scale learning collaboratives and initiatives have resulted in reduction in premature mortality, maternal and neonatal mortality, transmission of HIV from mother to child, as well as improved clinical processes. She is a seasoned faculty, teaching in in-person and virtually, in the multiple QI capacity building programs run by IHI across several countries for the past seven years. ​​​​​​

Michael PosenchegMichael A. Posencheg, MD, Chief Medical Officer, Penn Presbyterian Medical Center, and Attending Neonatologist, Children's Hospital of Philadelphia, has a particular interest in the areas of Quality Improvement and Patient Safety. He completed the Improvement Advisor (IA) and Graduate IA program at the Institute for Healthcare Improvement. While the Medical Director of the Intensive Care Nursery at the Hospital of the University of Pennsylvania, his team made significant improvements in reducing unplanned extubations in ventilated infants, redesigning delivery room care and improving admission temperatures for infants with a birth weight <1250g, reducing methicillin-resistant Staphylococcus aureus colonization, and standardizing the management of apnea of prematurity. As the Associate CMO for Penn Medicine, Dr. Posencheg led a team to organize and execute system wide projects together with entity based clinical teams to improve clinical outcomes and reduce cost. The projects have focused on reducing aspiration pneumonia and Clostridium Difficile infections, decreasing ventilator days and days of delirium in ICU patients, as well as initiatives for enhanced recovery after surgery. Dr. Posencheg is a Professor of Clinical Pediatrics at the Perelman School of Medicine of the University of Pennsylvania.

​​​​​​​​Disclaimer: Consistent with the IHI’s policy, faculty for this program are expected to disclose at the beginning of their presentation(s) any economic or other personal interests that create, or may be perceived as creating, a conflict related to the material discussed. The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. 

Unless otherwise noted below, each presenter provided full disclosure information, does not intend to discuss an unapproved/investigative use of a commercial product/device, and has no significant financial relationship(s) to disclose. If unapproved uses of products are discussed, presenters are expected to disclose this to participants.